LEO LUZNIK to Chronic Disease
This is a "connection" page, showing publications LEO LUZNIK has written about Chronic Disease.
Connection Strength
0.677
-
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
Score: 0.142
-
Notching up B-cell pathology in chronic GVHD. Blood. 2017 11 09; 130(19):2053-2054.
Score: 0.108
-
STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010 Jan 15; 184(2):764-74.
Score: 0.062
-
Chronic graft-versus-host disease: unresolved complication or ancient history? Blood. 2024 09 26; 144(13):1363-1373.
Score: 0.043
-
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997.
Score: 0.037
-
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021 06; 27(6):452-466.
Score: 0.034
-
Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
Score: 0.031
-
Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
Score: 0.030
-
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
Score: 0.029
-
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Feb; 23(2):211-234.
Score: 0.025
-
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7.
Score: 0.024
-
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
Score: 0.024
-
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2115-2122.
Score: 0.023
-
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
Score: 0.021
-
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
Score: 0.018
-
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1279-87.
Score: 0.014
-
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr; 12(4):414-21.
Score: 0.012